21514-99-8

Basic information

• Product Name: [6-(HYDROXYMETHYL)PYRIDIN-3-YL]METHANOL
• Synonyms: [6-(HYDROXYMETHYL)PYRIDIN-3-YL]METHANOL;2,5-Pyridinedimethanol;pyridine-2,5-diyldimethanol
• CAS NO: 21514-99-8
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15
• Mol File: 21514-99-8.mol
• Article Data: 14

Chemical Properties

• Melting Point: 157 °C
• Boiling Point: 326.2±32.0 °C(Predicted)
• Appearance: /
• Density: 1.261±0.06 g/cm3(Predicted)
• PKA: 13.50±0.10(Predicted)
• CAS DataBase Reference: [6-(HYDROXYMETHYL)PYRIDIN-3-YL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [6-(HYDROXYMETHYL)PYRIDIN-3-YL]METHANOL(21514-99-8)
• EPA Substance Registry System: [6-(HYDROXYMETHYL)PYRIDIN-3-YL]METHANOL(21514-99-8)

Safety Data

• Hazardous Substances Data: 21514-99-8(Hazardous Substances Data)

Usage

General Description

[6-(Hydroxymethyl)pyridin-3-yl]methanol is a chemical compound with the molecular formula C8H9NO2. It is a derivative of pyridine, containing a hydroxymethyl group and a methanol group attached to the pyridine ring. [6-(HYDROXYMETHYL)PYRIDIN-3-YL]METHANOL is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and organic compounds. It has a wide range of potential applications in the chemical and pharmaceutical industries due to its unique structure and reactivity. Additionally, it may also be used as a reagent in organic synthesis for the construction of more complex molecules. Overall, [6-(Hydroxymethyl)pyridin-3-yl]methanol has significant potential as a versatile and valuable chemical building block for the synthesis of various compounds.

Upstream product

• 55273-56-8 2,5-bis-acetoxymethyl-pyridine 
• 881-86-7 dimethyl 2,5-pyridine dicarboxylate 
• 5552-44-3 ethyl 2,5-pyridinedicarboxylate 
• 100-26-5 Pyridine-2,5-dicarboxylic acid 
• 5620-35-9 pyridine-2,5-dicarboxylic acid dichloride 

Downstream Products

• 40749-33-5 5-(hydroxymethyl)-2-pyrimidinecarboxaldehyde 
• 1375006-73-7 5-(azidomethyl)-2-((4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridine 
• 1375006-81-7 (1-((6-((4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methanol 
• 1375006-82-8 (1-((5-((4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methanol 
• 1375006-83-9 5-((4-butyl-1H-1,2,3-triazol-1-yl)methyl)-2-((4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridine 
• 1375006-84-0 5-((4-butyl-1H-1,2,3-triazol-1-yl)methyl)-2-((4-(p-tolyl)-1H-1,2,3-triazol-1-yl)methyl)pyridine 
• 86238-83-7 (E)-1-(2-carbethoxy-5-pyridyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)butadiene 
• 50501-35-4 5-(Hydroxymethyl)-2-pyridincarbonsaeure-ethylester 
• 39977-41-8 5-(hydroxymethyl)picolinic acid 
• 37877-95-5 [2](1,4)benzeno[2](2,5)pyridinophane 
• 42239-18-9 2,5-bis(bromomethyl)pyridine 

Relevant articles and documents

New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone Hybrids: Insights into the Anticancer and Antibacterial Mode of Action

Six morpholine-(iso)thiosemicarbazone hybrids HL1-HL6 and their Cu(II) complexes with good-to-moderate solubility and stability in water were synthesized and characterized. Cu(II) complexes [Cu(L1-6)Cl] (1-6) formed weak dimeric associates in the solid state, which did not remain intact in solution as evidenced by ESI-MS. The lead proligands and Cu(II) complexes displayed higher antiproliferative activity in cancer cells than triapine. In addition, complexes 2-5 were found to specifically inhibit the growth of Gram-positive bacteria Staphylococcus aureus with MIC50 values at 2-5 μg/mL. Insights into the processes controlling intracellular accumulation and mechanism of action were investigated for 2 and 5, including the role of ribonucleotide reductase (RNR) inhibition, endoplasmic reticulum stress induction, and regulation of other cancer signaling pathways. Their ability to moderately inhibit R2 RNR protein in the presence of dithiothreitol is likely related to Fe chelating properties of the proligands liberated upon reduction.

Development of Gene-Targeted Polypyridyl Triplex-Forming Oligonucleotide Hybrids

In the field of nucleic acid therapy there is major interest in the development of libraries of DNA-reactive small molecules which are tethered to vectors that recognize and bind specific genes. This approach mimics enzymatic gene editors, such as ZFNs, TALENs and CRISPR-Cas, but overcomes the limitations imposed by the delivery of a large protein endonuclease which is required for DNA cleavage. Here, we introduce a chemistry-based DNA-cleavage system comprising an artificial metallo-nuclease (AMN) that oxidatively cuts DNA, and a triplex-forming oligonucleotide (TFO) that sequence-specifically recognises duplex DNA. The AMN-TFO hybrids coordinate CuII ions to form chimeric catalytic complexes that are programmable – based on the TFO sequence employed – to bind and cut specific DNA sequences. Use of the alkyne-azide cycloaddition click reaction allows scalable and high-throughput generation of hybrid libraries that can be tuned for specific reactivity and gene-of-interest knockout. As a first approach, we demonstrate targeted cleavage of purine-rich sequences, optimisation of the hybrid system to enhance stability, and discrimination between target and off-target sequences. Our results highlight the potential of this approach where the cutting unit, which mimics the endonuclease cleavage machinery, is directly bound to a TFO guide by click chemistry.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.